Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

267.30SEK
22 Aug 2018
Change (% chg)

0.10kr (+0.04%)
Prev Close
267.20kr
Open
266.90kr
Day's High
267.50kr
Day's Low
266.40kr
Volume
13,896
Avg. Vol
869,364
52-wk High
271.30kr
52-wk Low
107.40kr

Summary

Name Age Since Current Position

Hakan Bjorklund

61 2016 Independent Chairman of the Board

Guido Oelkers

53 2017 President, Chief Executive Officer

Henrik Stenqvist

51 2018 Chief Financial Officer

Armin Reininger

60 2017 Senior Vice President, Medical and Scientific Affairs

Lars Dreioee

50 2016 Senior Vice President, Chief Quality & Compliance Officer

Dennis Schmidt Pedersen

47 2013 Senior Vice President Human Resources

Kirsti Gjellan

54 Senior Vice President, Head of Biologics Development & Supply

Wills Hughes-Wilson

46 Senior Vice President and Chief Patient Access Officer

Milan Zdravkovic

47 2016 Senior Vice President, Head of Research & Development

Fredrik Berg

62 Vice President, General Counsel, Head Legal & Intellectual Property, Risk- Safety and Environment Management

Trista Morrison

2017 Vice President - Communications for North America

David Allsop

55 2018 Director

Lennart Johansson

63 2010 Director

Bo-Gunnar Rosenbrand

54 2006 Director, Employee Representative

Helena Saxon

48 2011 Director

Elisabeth Svanberg

57 2018 Director

Annette Clancy

63 2014 Independent Director

Matthew Gantz

52 2012 Independent Director

Hans Schikan

60 2011 Independent Director

Jorgen Winroth

2012 Vice President, Head of Investor Relations

Biographies

Name Description

Hakan Bjorklund

Dr. Hakan Bjorklund, Ph.D. has been Independent Chairman of the Board at Swedish Orphan Biovitrum AB (publ) since May 24, 2016. He is Chairman of Compensation & Benefits Committee. He has an extensive international background in the life science industry, from both R&D and sales and marketing. He has experience of leading healthcare companies in expansive development phases. He has been CEO, Nycomed; Member of the Board of Directors, Alere, Coloplast, Danisco, and Lundbeck and Board Member, Biovitrum 2001- 2007. He is Industry Executive, Avista Capital Partners; Member of the Board of Directors of Bonesupport, Acino and Trimb. He holds Ph.D., Karolinska Institutet, Stockholm, Sweden.

Guido Oelkers

Mr. Guido Oelkers, Ph.D. has been appointed President and Chief Executive Officer at Swedish Orphan Biovitrum AB (publ) effective as of May 22, 2017. Guido Oelkers joined Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda. Guido Oelkers holds a Ph.D. in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He completed his postgraduate studies in Economics at London School of Economics and Political Science.

Henrik Stenqvist

Mr. Henrik Stenqvist has been appointed Chief Financial Officer at Swedish Orphan Biovitrum AB (publ) effective as of late spring 2018 (around June 2018). Henrik Stenqvist has comprehensive experience from the pharmaceutical industry with 25 years in finance and management positions. He joins Sobi from a position as CFO of Recipharm. Prior to that, Henrik Stenqvist served as the CFO of the Meda Group, where he played an instrumental role in the transformation of Meda from a small Nordic player to a leading international specialty pharma, executing numerous acquisitions as well as the integration of these. Henrik Stenqvist holds a degree in Finance and Business Administration from the University of Linkoping, Sweden.

Armin Reininger

Mr. Armin Reininger, M.D., Ph.D. has been Senior Vice President, Medical and Scientific Affairs at Swedish Orphan Biovitrum AB (publ) since January 1, 2017. Armin joined Sobi from Shire/Baxalta where he for the past 6 years has developed the Medical Affairs team within hemophilia and hematology as Head of Medical Affairs EMEA and Head of Medical Affairs Global, respectively. He has been Visiting Scientist-Visiting Lecturer Harvard Medical School, Mass. General Hospital, Boston, MA, Visiting Fellow The Scripps Research Institute, La Jolla, CA, Professor of Anatomy at the Ludwig Maximilians-University Munich, Germany. He holds M.D., Ph.D., Ludwig-Maximilians-University Munich, Germany; and is certified specialist in Transfusion Medicine.

Lars Dreioee

Mr. Lars Dreioee has been appointed Senior Vice President, Chief Quality & Compliance Officer at Swedish Orphan Biovitrum AB (publ) effective as of January 18, 2016. He joined the Company from global pharmaceutical company ALK in Denmark where he has been International Head of Quality. Lars brings 20 years of experience in the Biotech and Pharmaceutical industry at Lundbeck and Novo Nordisk A/S. He holds M. Sc. University of Southern Denmark, Executive MBA from Copenhagen Business School.

Dennis Schmidt Pedersen

Mr. Dennis Schmidt Pedersen has been appointed Senior Vice President Human Resources of Swedish Orphan Biovitrum AB (publ), effective as of October 2013. He joined the Company from global pharmaceutical company Takeda where he held the position as Director Human Resources, Northern Europe. Mr. Schmidt Pedersen has experience from managerial positions held in several international companies including Genzyme, Ferring Pharmaceuticals and A.P. Moeller-Maersk. He is trained officer from the Royal Danish Officers Academy, specialized in leadership development, analytical studies and tactics.

Kirsti Gjellan

Ms. Kirsti Gjellan serves as Senior Vice President, Head of Biologics Development & Supply at Swedish Orphan Biovitrum AB (publ). She joined the Company in 2014. She is Pharmacist and holds a Doctorate of Philosophy degree in Pharmaceutical Technology from Universitetet i Oslo. Previously she was Factory Director, Biologics Manufacturing, MD at Pfizer Health AB (2010-2014) and Board Member of Pfizer Health AB (2011-2014). She was also Director of Quality Operations, Pfizer (2005-2010). She has 17 years of experience from senior positions in research and manufacturing medicines at Astra Zeneca. She is also Board member of Processindustriell IT and Automation (PiiA).

Wills Hughes-Wilson

Ms. Wills Hughes-Wilson serves as Senior Vice President and Chief Patient Access Officer in Swedish Orphan Biovitrum AB (publ). She joined the Company in 2012. She comes from Genzyme Corporation, now part of the French Sanofi Group, where she was Vice President Health/Market Access Policy, EMEA (2005-2012). She joined Genzyme in 2005. Prior to Genzyme, she was Executive Director of Emerging Biopharmaceutical Enterprises (EBE), a specialized group of the European Federation of Pharmaceuticals Industries & Associations (EFPIA) representing the interest of biotechnology companies in Europe. She also worked in the animal health/veterinary medicines industry and at Ernst & Young Consulting. She is an Honors graduate with Bachelor of Law from University of Durham in the United Kingdom.

Milan Zdravkovic

Mr. Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development of Swedish Orphan Biovitrum AB (publ), effective as of November 1, 2016. He joined Sobi from Novo Nordisk where he has had a 18-year tenure in the Research and Development organization responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity. He is DIA Advisory Council Europe, Middle East and Africa, Board member and co-founder of Selma Diagnostics Aps. He holds M.D., Ph.D. University of Aarhus, Denmark, M.Sc. Pharmaceutical Medicine, University of Surrey, United Kingdom.

Fredrik Berg

Mr. Fredrik Berg is Vice President, General Counsel, Head Legal & Intellectual Property, Risk- Safety and Environment Management at Swedish Orphan Biovitrum AB (publ) (previously Biovitrum AB). He has been employed by the Company since 2001. He started his legal career at the law firm Tisell & Co (1984-1988), and later on joined KabiVitrum in 1988. He held various positions such as Company Lawyer and Head of Legal Services at Procordia, Kabi Pharmacia and Pharmacia & Upjohn. In 1996, he joined the law firm Lindahl, but was recruited back to Pharmacia in 1997. Prior to joining Biovitrum, he was Head of Legal and Intellectual Property at Pharmacia AB and General Counsel at Pharmacia Europe, Middle East and Africa (1997-2001). Mr. Berg holds a Master of Legal Letters degree from Stockholms universitet.

Trista Morrison

Ms. Trista Morrison is Vice President - Communications for North America of the Company. Morrison's more than 15 years in biopharmaceutical communications span corporate, reporter and agency roles. Most recently, Morrison served as director of corporate communications for Ironwood Pharmaceuticals, where she led internal, external and brand communications as the company transitioned from a research and development organization to a fully integrated commercial biotechnology company. Prior to her role at Ironwood, Morrison served as an editor and staff writer at BioWorld Today, covering breaking news and trends in the biopharmaceutical industry. Previously she served in various positions with biopharmaceutical-focused public relations agency Porter Novelli Life Sciences (formerly Atkins + Associates). Morrison was honored as one of PR News' Top Women in PR in 2017, which recognizes communicators who have made bold advances in the profession.

David Allsop

Mr. David Allsop has been Director of Swedish Orphan Biovitrum AB (publ) since May 9, 2018. He has a BSc Hons Chemistry from Coventry University, UK. Through his company U-R-NOT Ltd., Mr. Allsop offers advisory services to the pharma industry. He has international experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Further, Mr. Allsop has experience from successfully launching blockbuster biologics across the entire world. Until January 2018, he was Head of International in Amicus Therapeutics Ltd. Before then Mr. Allsop held a number of senior positions in Biogen 1998–2015.

Lennart Johansson

Mr. Lennart Johansson has been Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) (previously Biovitrum AB) since April 27, 2010. He also serves as Chairman of the Company's Audit Committee. Mr. Johansson is Member of the management team and Senior Advisor in Patricia Industries, Board member of Hi3G, Chairman of the Board of Vectura AB and deputy Board member of Molnlycke Health Care. Formerly, he held the position of Chief Executive Officer at b-business partners and Emerging Technologies AB. He was also Board member of SAAB AB, IBX Group AB, Gambro Holding AB, Member of Investor AB management team. He holds a Master of Business Administration degree from Handelshogskolan i Stockholm.

Bo-Gunnar Rosenbrand

Mr. Bo-Gunnar Rosenbrand has been Employee Representative on the Board of Directors of Swedish Orphan Biovitrum AB (publ) (previously Biovitrum AB) since 2006. He was Deputy Member of the Board of the Company between 2001 and 2005. He is Laboratory Engineer and represents Federation of Salaried Employees in Industry and Services (PTK).

Helena Saxon

Ms. Helena Saxon has served as Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) since April 28, 2011. She also serves as Member of the Company's Audit Committee and Compensation and Benefits Committee. She holds a Master of Business Administration degree from Handelshogskolan i Stockholm. She is also CFO at Investor AB and Board Member of SEB. Previously, she served as Chief Financial Officer of Hallvarsson & Halvarsson, Vice President of Investor AB and financial analyst at Goldman Sachs, as well as Board member of Aleris, Gambro and Molnlycke Health Care.

Elisabeth Svanberg

Ms. Elisabeth Svanberg has been Director of Swedish Orphan Biovitrum AB (publ) since May 9, 2018. She has a MD and PhD from the University of Gothenburg, Sweden. Ms. Svanberg is associate professor of surgery and is serving as Chief Development Officer at Ixaltis SA since 2016. She is member of the Board of Directors of Follicum AB and PledPharma AB, and has also served as board member of the Swedish American Chamber of Commerce New York. Previously she was Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016 and has worked with Bristol Myers Squibb (BMS) in the US leading the development of a novel diabetes medicine and subsequently served as Head of Medical Affairs for the Intercontinental region. 2000–2007, Ms. Svanberg worked at Serono International in the field of metabolism.

Annette Clancy

Ms. Annette V. Clancy has been Independent Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) since May 8, 2014. She is Member of the Scientific Committee. Ms. Clancy has over 30 years of experience in the Pharmaceutical and Biotechnology Industry, working in a variety of roles in the United States and United Kingdom. She has a Bachelor of Science Hons in Pharmacology, from Bath University UK. She is Non-executive Chairman of the Board of Enyo SA and Lysogene SA and Senior European Advisor to the Biopharmaceutical Team of Frazier Healthcare Ventures. She is also Board Member of Obseva SA. She was Head of Transaction and Alliance Management at GlaxoSmithKline (GSK).Since her retirement from GSK in 2008, Ms. Clancy has been appointed as Non-Executive Board Director to Silence Therapeutics plc. (2008-2012) and Clavis Pharma in Norway (2010-2013). She was also Chair of the Board of Genable Therapeutics.

Matthew Gantz

Mr. Matthew Gantz has served as Independent Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) since April 26, 2012. He is Member of Life Science Pennsylvania Industry Board. He was previously Executive Vice President in BTG, an international healthcare company. Previously, he founded and served as Chief Executive Officer (CEO) of Acureon Pharmaceuticals. Is the past, he was also President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, he held a variety of United States sales and marketing roles at Abbott Laboratories Diagnostic Division. Mr. Gantz holds a Bachelor of Arts degree from Princeton University and a Master of Business Administration degree from Harvard Business School.

Hans Schikan

Mr. Hans GCP Schikan has served as Independent Member of the Board Directors of Swedish Orphan Biovitrum AB (publ) since April 28, 2011. He is also Member of the Company's Audit and Scientific Committees. He holds a Pharm.D degree from Universiteit Utrecht. He also serves as Chairman of the Board of Asceneuron in Switzerland, Interna Technologies and Complix, Board member of Hansa Medical, Therachon, Wilson Therapeutics and the Dutch Top Sector Life Sciences & Health and Advisor to various organizations in the Life Sciences & Health. Previously, he was CEO of Prosensa and member of Prosensa’s Supervisory Board, Board member of Top Institute Pharma, Chairman of Nefarma, the association for innovative medicines in the Netherlands, and a number of senior positions in the former Organon and Genzyme.

Jorgen Winroth

Mr. Jorgen Winroth has been appointed Vice President, Head of Investor Relations at Swedish Orphan Biovitrum AB (publ), effective as of November 16, 2012. He has served as Director, Investor Relations for AstraZeneca North America for the past sixteen years. He has also served as Consultant providing strategic Investor Relations services to a number of Scandinavian companies including Hafslund Nycomed AS, AB SKF, Huhtamaki Oy. He also served as Vice President, Investor Relations at Pharmacia.